List of Mitsubishi Tanabe Pharma patents

Patents where

Current Assignee

Name

Mitsubishi Tanabe Pharma

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9758578 Human anti-IL-33 neutralizing monoclonal antibody	Patent 9758578 was granted and assigned to Mitsubishi Tanabe Pharma on September, 2017 by the United States Patent and Trademark Office.	Mitsubishi Tanabe Pharma	Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	9758578	September 12, 2017
‌ US Patent 7527935 G-protein coupled receptor having eicosanoid as ligand and gene thereof	Patent 7527935 was granted and assigned to Mitsubishi Tanabe Pharma on May, 2009 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	7527935	May 5, 2009
‌ US Patent 9125915 Antitumor agent	Patent 9125915 was granted and assigned to Mitsubishi Tanabe Pharma on September, 2015 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	9125915	September 8, 2015
‌ US Patent 11471452 Compositions and methods for treating or preventing vasomotor symptoms	Patent 11471452 was granted and assigned to Mitsubishi Tanabe Pharma on October, 2022 by the United States Patent and Trademark Office.	Mitsubishi Tanabe Pharma	Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	11471452	October 18, 2022
‌ US Patent 8084611 Process for preparing tetrahydroquinoline derivatives	Patent 8084611 was granted and assigned to Mitsubishi Tanabe Pharma on December, 2011 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	8084611	December 27, 2011
‌ US Patent 7504423 α-amino acid derivatives and use thereof as medicines	Patent 7504423 was granted and assigned to Mitsubishi Tanabe Pharma on March, 2009 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	7504423	March 17, 2009
‌ US Patent 7488591 Process for producing protein with reduction of acidic sugar chain and glycoprotein produced thereby	Patent 7488591 was granted and assigned to Mitsubishi Tanabe Pharma on February, 2009 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	7488591	February 10, 2009
‌ US Patent 11478450 Edaravone suspension for oral administration	Patent 11478450 was granted and assigned to Mitsubishi Tanabe Pharma on October, 2022 by the United States Patent and Trademark Office.	Mitsubishi Tanabe Pharma	Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	11478450	October 25, 2022
‌ US Patent 10407408 Imide derivatives and use thereof as medicine	Patent 10407408 was granted and assigned to Mitsubishi Tanabe Pharma on September, 2019 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	10407408	September 10, 2019
‌ US Patent 7872006 Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity	Patent 7872006 was granted and assigned to Mitsubishi Tanabe Pharma on January, 2011 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	7872006	January 18, 2011
‌ US Patent 11299547 CMET monoclonal binding agents, drug conjugates thereof and uses thereof	Patent 11299547 was granted and assigned to Mitsubishi Tanabe Pharma on April, 2022 by the United States Patent and Trademark Office.	Mitsubishi Tanabe Pharma	Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	11299547	April 12, 2022
‌ US Patent 11241416 Edaravone suspension for oral administration	Patent 11241416 was granted and assigned to Mitsubishi Tanabe Pharma on February, 2022 by the United States Patent and Trademark Office.	Mitsubishi Tanabe Pharma	Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	11241416	February 8, 2022
‌ US Patent 10987341 Edaravone suspension for oral administration	Patent 10987341 was granted and assigned to Mitsubishi Tanabe Pharma on April, 2021 by the United States Patent and Trademark Office.	Mitsubishi Tanabe Pharma	Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	10987341	April 27, 2021
‌ US Patent 7935700 Morpholine compound	Patent 7935700 was granted and assigned to Mitsubishi Tanabe Pharma on May, 2011 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	7935700	May 3, 2011
‌ US Patent 7666869 Nitrogen-containing 5-membered ring compound	Patent 7666869 was granted and assigned to Mitsubishi Tanabe Pharma on February, 2010 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	7666869	February 23, 2010
‌ US Patent 9540360 Sulfonamide compounds having TRPM8 antagonistic activity	Patent 9540360 was granted and assigned to Mitsubishi Tanabe Pharma on January, 2017 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	9540360	January 10, 2017
‌ US Patent 7544841 Production method of phenylethanolamine compound, and its intermediate	Patent 7544841 was granted and assigned to Mitsubishi Tanabe Pharma on June, 2009 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	7544841	June 9, 2009
‌ US Patent 8183206 Drugs comprising combination of antithrombotic agent with pyrazolone derivative	Patent 8183206 was granted and assigned to Mitsubishi Tanabe Pharma on May, 2012 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	8183206	May 22, 2012
‌ US Patent 7872151 Inhibitors of α	Patent 7872151 was granted and assigned to Mitsubishi Tanabe Pharma on January, 2011 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	7872151	January 18, 2011
‌ US Patent 11890288 Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof	Patent 11890288 was granted and assigned to Mitsubishi Tanabe Pharma on February, 2024 by the United States Patent and Trademark Office.	Mitsubishi Tanabe Pharma	Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	11890288	February 6, 2024
‌ US Patent 8034949 Pyrrolidine compound and a process for preparing the same	Patent 8034949 was granted and assigned to Mitsubishi Tanabe Pharma on October, 2011 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	8034949	October 11, 2011
‌ US Patent 7342012 Inhibitors of α	Patent 7342012 was granted and assigned to Mitsubishi Tanabe Pharma on March, 2008 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	7342012	March 11, 2008
‌ US Patent 8791266 Thyroid hormone β receptor agonist	Patent 8791266 was granted and assigned to Mitsubishi Tanabe Pharma on July, 2014 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	8791266	July 29, 2014
‌ US Patent 8119626 Oxime derivative and preparations thereof	Patent 8119626 was granted and assigned to Mitsubishi Tanabe Pharma on February, 2012 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	8119626	February 21, 2012
‌ US Patent 8410166 Fused bicyclic compound	Patent 8410166 was granted and assigned to Mitsubishi Tanabe Pharma on April, 2013 by the United States Patent and Trademark Office.		Mitsubishi Tanabe Pharma	United States Patent and Trademark Office	8410166	April 2, 2013

Results per page:

96 results

0 selected

96 results

0 selected